Prosecution Insights
Last updated: November 04, 2026
Application No. 18/023,576

MULTI-PATCH VACCINES AND IMMUNOGENIC COMPOSITIONS, METHODS OF PRODUCTION AND USES THEREOF

Non-Final OA §102§112§OTHER
Filed
Feb 27, 2023
Priority
Sep 01, 2020 — IN 202011037585 +2 more
Examiner
BLUMEL, BENJAMIN P
Art Unit
1671
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sukrit Srivastava
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
739 granted / 1046 resolved
+10.7% vs TC avg
Strong +31% interview lift
Without
With
+31.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
64 currently pending
Career history
1109
Total Applications
across all art units

Statute-Specific Performance

§101
5.8%
-34.2% vs TC avg
§103
32.0%
-8.0% vs TC avg
§102
15.1%
-24.9% vs TC avg
§112
29.5%
-10.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1046 resolved cases

Office Action

§102 §112 §OTHER
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election of invention I and the required species in the reply filed on 8/3/26 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Presently, SARS-CoV-2 or a proteome of SARS-CoV-2 is not claimed, therefore, this elected species will not be examined. Claims 13-19 and 21 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 8/3/26. Claims 1-12 are examined on the merits. Information Disclosure Statement The information disclosure statement (IDS) submitted on 5/11/23 and 3/11/25 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered. Drawings The drawings are objected to because the text presented in Figures 1-3 is unclear and can’t be read in its entirety. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-12 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The following quotation from section 2163 of the Manual of Patent Examination Procedure is a brief discussion of what is required in a specification to satisfy the 35 U.S.C. 112 written description requirements for a generic claim covering several distinct inventions: The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice .... reduction to drawings .... or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus... See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406. A "representative number of species" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. Thus, when a claim covers a genus of inventions, the specification must provide written description support for the entire scope of the genus. Support for a genus is generally found where the applicant has provided a number of examples sufficient so that one in the art would recognize from the specification the scope of what is being claimed. Claims 1-12 are rejected as lacking adequate descriptive support for a method for producing an immunogenic composition of peptide sequences from at least one proteome of interest, comprising the steps of: a) providing multiple epitope sequences from said at least one proteome of interest, b) aligning the multiple epitope sequences of a) in order to generate at least one immunogenic peptide sequence comprising an Ag-patch, consisting of at least two overlapping epitope sequences from a region of a polypeptide from said at least one proteome of interest, and c) combining said Ag-Patch into an immunogenic polypeptide construct, the construct comprising at least one Ag-Patch, at least one linker peptide sequence, and optionally, at least one adjuvant peptide sequence, and thereby producing an immunogenic composition of peptide sequences from at least one proteome of interest. The proteome of interest is from a virus. In support of the claimed genus (employing a proteome of a virus to produce an antigen-patch), the application discloses one example in which the proteome of SARS-CoV-2, specifically the genome of isolate Wuhan-Hu-1, is used to produce an antigen-patch. No other examples or derivatives or variants or mutants thereof are disclosed in the manufacturing of an immunogenic composition of peptide sequences from at least one proteome of interest, such as that of a virus. Thus, the application fails to provide a representative number of proteomes of interest from viruses that would be used to produce the claimed antigen-patch and immunogenic composition. Maxwell et al. (MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, June2007, p.398–411, Vol.71, No.2) provide a review of the proteomics of viruses. For example, viral proteomes are diverse, with mimi viruses possessing a genome of 1.2-megabases surpasses the size of several bacterial genomes, and its 1,262 potential proteins [see page 391, right column], SARS viruses possess a smaller genome by comparison and therefore a smaller proteome, and that other viral proteomes possess viral proteins and host cell proteins [see page 402, left column]. Maxwell et al. provides evidence that viral proteomes are diverse and complex. Thus, in view of the above, there would have been significant uncertainty as to which viral proteomes, other than SARS-CoV-2, and be able confer the claimed generation of an immunogenic composition based on antigen patch generation. In view of this uncertainty and the lack of any examples of the claimed genus, the claims are rejected for lack of adequate written description support. following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-12 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claims 1, 2, 7 and 8 recites the broad recitation “antigenic patch”, and the claim also recites “(Ag-Patch or epitope sequences patches)” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Claims 4-6 and 9-12 are also rejected because they depend from claim 1, but do not remedy this deficiency. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 10 recites the broad recitation “human P defensin 2”, and the claim also recites “(GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP) (SEQ ID NO: 128)” and the claim recites the broad recitation “human P defensin 3”, and the claim also recites “(GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRG-RKCCRRKK) (SEQ ID NO: 129)” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Claim interpretation Applicant’s invention requires the use of an antigen patch or Ag-patch or epitope sequences patches. To better understand what this encompasses, figure 2 provides a visual of how such patch or patches can be arrived at. Also, claim 1 recites, “aligning the multiple epitope sequences…consisting of at least two overlapping epitope sequences from a region of a polypeptide from said at least one proteome of interest…” PNG media_image1.png 685 948 media_image1.png Greyscale It would appear that Step 2 involves this “overlapping” step, which appears to be generating an Ag-Patch that possesses a conserved motif or amino acid sequence. Therefore, if the prior art teach generating fusion proteins comprising at least two conserved epitopes of viral proteins, which are generated by comparing overlapping amino acid sequences, and which are linked together, then the prior art would be teaching a method of generating an antigen patch. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-12 are rejected under 35 U.S.C. 102a1 as being anticipated by Jain et al. (bioRxiv, 2020). Jain et al. teaches an approach to construct a multi-epitope vaccine candidate against with high antigenicity, safety and efficacy comprising scrutinizing the whole proteome for the screening of highly conserved, antigenic, non-allergen and non-toxic epitopes among both structural and non-structural accessory proteins of the virus and having high population coverage, that can elicit both humoral and cellular mediated immune response against COVID-19 infection (see abstract and page 3). Said method comprised providing multip1e epitope sequences from the proteome of SARS-COV-2, selection Of epitopes having 100% conservation among all the epitopes which hence read on antigenic patches since the portion conserved among all epitopes is chosen, evaluation of allergenicity and toxicity inside the host, and design of vaccine construct by joining the selected best HTL, CTL and B-cell epitopes GPGPG, AAG and KK linkers and further adjuvant peptides like beta-defensin, universal memory T cell helper peptide (TpD), PADRE sequence etc using EAAAK linker. A specific example of the adjuvant is identical to SEQ ID NO: 129 of the instant invention. The screened epitopes covered fifteen various antigenic proteins of including various non-structural (nsp2, nsp4, nsp6, Guanine N7 methyltransferase (EXON), etc., structural (E, M, N and S) and accessory proteins (ORF3a, ORF7a and ORFO thereby making the resultant vaccine most antigenic and potent, and the resultant DNA was further codon optimized and a six histidine tag at the 3’ end for isolation and purification (see Materials and Methods and figures 4 & 9C). The antigenic viral proteins were screened for the most immunogenic and antigenic B-cell and T-cell epitopes that could be successfully recognized by various HLA alleles (14 HLA I and 20 HLA II, covering of the world population) and efficiently evoke the immune response (see results and discussion). Therefore, Jain et al. anticipate the instant invention. Claim(s) 1-8 and 12 are rejected under 35 U.S.C. 102a1 as being anticipated by Srivastava et al. (Journal of Biomolecular structure and Dynamics, 2019, 37 (16) :4345-4360). Srivastava et al. teaches the design of multi-epitope vaccines (MEVs) against SARS-COV composed of cytotoxic T lymphocyte (CTL) , helper T lymphocyte (HTL) and B cell epitopes' overlap (and hence they are antigenic patches), bearing the potential to elicit cellular as well as humoral immune response. Selected overlapping epitopes of both the MEVs were further validated for stable molecular interactions with their respective human leukocyte antigen class I and II allele binders, transporter associated with antigen processing and also Toll-Like Receptors 2 and 4 (see abstract) . The method of design of MEVS comprised screening of CTL, HTL and B cell epitopes from eleven SARS-CoV proteins followed by identification of overlapping consensus regions (which are nothing but antigenic patches), docking and molecular interaction studies and codon optimization for high-level expression in mammalian cells (see pages 4 & 6, and sections about prediction of epitopes under both methods and results). Therefore, Srivastava et al. anticipate the instant invention. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BENJAMIN P BLUMEL whose telephone number is (571)272-4960. The examiner can normally be reached M-F 8-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Allen can be reached at (571) 270-3497. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BENJAMIN P BLUMEL/Primary Examiner, Art Unit 1671
Read full office action

Prosecution Timeline

Feb 27, 2023
Application Filed
Oct 30, 2026
Non-Final Rejection mailed — §102, §112, §OTHER (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774309
TREATMENT OF HEPATIC AND CARDIOVASCULAR DISORDERS
4y 4m to grant Granted Oct 27, 2026
Patent 12746283
DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF
3y 8m to grant Granted Sep 29, 2026
Patent 12742213
PROTECTION SEQUENCE, PRIMER, PROBE, COMPOSITION AND KIT FOR STEADY-STATE RAPID DETECTION OF NOVEL CORONAVIRUS, AND USE THEREOF AND METHOD THEREFOR
3y 8m to grant Granted Sep 22, 2026
Patent 12741991
LIVE-ATTENUATED FLAVIVIRUSES WITH HETEROLOGOUS ANTIGENS
3y 4m to grant Granted Sep 22, 2026
Patent 12708654
NEW VIRUS PARTICLES FOR THERAPEUTIC PURPOSES
4y 5m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
99%
With Interview (+31.0%)
3y 2m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1046 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month